Bio-Techne Corp. plans to sell its Exosome Diagnostics Inc. business to Mdxhealth SA for $15 million plus royalty payments, a steep cut from the $250 million the company paid to acquire Exodx in 2018.

Major indices delivered solid gains on Wednesday as market participants thumbed over a fresh batch of corporate earnings.

We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the ...

Wall Street trading got off to a mixed start on Wednesday as market participants thumbed over a fresh batch of corporate ...

Apple (NASDAQ:AAPL) stock rose 1.25% in pre-market trading Wednesday following comments from National Economic Council ...

Metro Bank Holdings PLC (NYSE: MCB) (LSE:MTRO) results are flagged by market analyst Victoria Scholar at Interactive Investor ...

September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning as investors digested U.S. President Donald ...

NasdaqGS:VRTX 1 Year Share Price vs Fair Value Explore Vertex Pharmaceuticals's Fair Values from the Community ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising ...